Please ensure Javascript is enabled for purposes of website accessibility

Why Organogenesis Holdings Blasted 7.7% Higher Today

By Eric Volkman - May 27, 2021 at 5:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company will be a component of a high-profile stock index.

What happened

Organogenesis Holdings (ORGO -6.62%), a regenerative health products specialist, shot skyward Thursday thanks to its inclusion on a key stock market index.

So what

On Wednesday, after market close, S&P Dow Jones Indices -- operator of the famous S&P family of indexes -- announced a pair of changes to two of those indexes. Organogenesis healthcare sector peer Cantel Medical is being removed from the S&P MidCap 400 index, as it's being acquired by Steris.

Man attending to a child's leg injury.

Image source: Getty Images.

Cantel, therefore, needs to be replaced, and the chosen party is shoe maker Crocs, currently a component of the S&P SmallCap 600 index. Since Crocs is vacating its S&P SmallCap 600 index spot, it also must have a successor, and Organogenesis has been tapped for the position.

These changes will be effective prior to market open next Wednesday, June 2.

Since S&P indexes are considered by many investors to be the benchmark equities indicators, inclusion on one instantly raises a company's profile. So it is with Organogenesis, a young healthcare company that has shown strong growth and more habitual profitability of late but was largely unknown by the general investing public.

Now what

Inclusion on any index, no matter how high profile, barely -- if at all -- affects a company's fundamentals or business strategy. Organogenesis will now be targeted by index funds trawling the S&P indicators for good growth stocks, but investors are better off buying the stock if they believe in its potential rather than its popularity.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Organogenesis Inc. Stock Quote
Organogenesis Inc.
$4.23 (-6.62%) $0.30
Cantel Medical Corp. Stock Quote
Cantel Medical Corp.
Steris Plc Stock Quote
Steris Plc
$210.22 (-1.22%) $-2.60
Crocs, Inc. Stock Quote
Crocs, Inc.
$72.85 (-5.29%) $-4.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.